Response by Traverse and Garberich to Letter Regarding Article, "NHLBI-Sponsored Randomized Trial of Postconditioning During Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction".
Response by Traverse and Garberich to Letter Regarding Article, "NHLBI-Sponsored Randomized Trial of Postconditioning During Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction".
复制标题
Traverse 和 Garberich 对有关文章“NHLBI 赞助的 ST 段抬高型心肌梗死初次经皮冠状动脉介入治疗期间的后处理随机试验”的信件的回应。
DOI:
10.1161/circresaha.119.314860
复制
发表时间:
2019
影响因子:
20.1
通讯作者:
Garberich,RossF
中科院分区:
文献类型:
--
作者:
Traverse,JayH;Garberich,RossF
We thank Drs Lou and Zhou for their comments1 regarding our National Heart, Lung, and Blood Institute-sponsored trial of postconditioning. 2 In our study, we observed that patients with ST-segment–elevation myocardial infarction (STEMI) randomized to postconditioning at the time of primary percutaneous coronary intervention experienced improved left ventricular (LV) remodeling when evaluated at 12 months by cardiac magnetic resonance imaging and that those patients had less microvascular obstruction in the infarct zone compared with the control group. However, these favorable effects on remodeling were not observed at the 3-month time point. The authors questioned whether the disparity in aspiration thrombectomy that favored the control group (24 [42%] versus 15 [23%] subjects; P= 0.034) was responsible for our failure to observe a similar improvement in remodeling at the 3-month time point.The authors cited several trials demonstrating a benefit of aspiration thrombectomy on LV volumes3 or microvascular obstruction 4, 5 during STEMI. Kondo et al3 compared 109 consecutive STEMI patients undergoing aspiration thrombectomy and percutaneous transluminal coronary angioplasty to a historical control group of 86 patients undergoing primary percutaneous transluminal coronary angioplasty. They observed that adverse LV remodeling defined as a> 20% increase in LV end-diastolic volume index, occurred significantly more frequently in the control group.